M
Medilink Therapeutics
Biotech company focusing on next-generation antibody-drug conjugate research and development
About Medilink Therapeutics
Medilink Therapeutics is a startup operating in the pharmaceutical industry, specifically in the Antibody-Drug Conjugates (ADC) field. ADCs are a type of targeted therapy that combines an antibody (a protein that can bind to a specific target on cancer cells) with a potent drug. Medilink's unique technology platform aims to develop better drugs with the potential to meet unmet clinical needs.
Read full description
The company's business model revolves around the continuous development and iteration of its technology to create and improve its products. It focuses on developing drug conjugates that are internationally competitive, leveraging the latest generation of technologies and products with independent intellectual property rights. This means that Medilink owns the rights to its unique technologies and products, which can provide a competitive advantage in the market.
Medilink serves a global patient base, aiming to expand into new disease areas to meet the needs of more patients. It has established a diverse technology platform for drug conjugates, which allows it to develop a variety of drugs for different diseases.
The company generates revenue through the development and sale of its drug conjugates. As it continues to grow and develop, it has gained the favor of many partners, which could potentially lead to collaborations or partnerships that could further boost its revenue and market presence.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Suzhou Shi, China
- Employees
- 61
- Open positions
- 1
- Dealroom signal
- 89.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Medilink Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Mar 2022 | $70M | $280M | Highlight Capital · Qiming Venture Partners · Legend Capital · Loyal Valley Capital | ↗ |
| SERIES AOther financing | Mar 2021 | $50M | $200M | Qiming Venture Partners · Loyal Valley Capital · Apricot Capital | — |
Growth signals
Latest recorded traffic for Medilink Therapeutics is 3.3K monthly website visits, up 83.3% over the last three months. Medilink Therapeutics's team grew 15.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Qiming Venture Partners
Loyal Valley Capital
Apricot Capital
LYFE Capital
Highlight Capital
Legend Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Medilink Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Medilink Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.